Reimb for Paxlovid still pending amid COVID-19 resurgence
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.08.12 05:09:55
가나다라
0
It has been prescribed to patients with mild symptoms due to confusion over prescription criteria
The Korean Disease Control and Prevention Agency (KDCPA) says, "Can only be used in patients 60 years and older who have severe symptoms"
Reimbursement criteria must be established to resolve confusion
▲Product photo of Paxlovid.
As the COVID-19 treatment supply becomes an ongoing issue amid a virus resurgence, clinical practices are frustrated by delayed reimbursement coverage of 'Paxlovid (nirmatrelvir‧ritonavir, Pfizer Korea).'The drug reimbursement application for Paxlovid was submitted to the Health Insurance Review and Assessment Service (HIRA) in early October of last year. After that, HIRA has yet to finish the evaluation.
On August 8th, Paxlovid was not considered for HIRA's Drug Reimbursement Evaluation Committee (DREC) review. Initially, Pfizer aimed to acquire reimbursement for Paxlovid for the first half of the year, but it has yet to be considered for the DREC review 10 months after submissio
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)